Finance

Lists
Why is DRREDDY down 2.51%?
Dive Deeper
DRREDDY:NSE
Dr Reddy's Laboratories Ltd
₹ 1,202.00
-2.51%
(-31.00) 1D
10-р сарын 1, 15:30:00 (GMT+5:30)  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for DRREDDY...
Open
₹ 1,233.00
High
₹ 1,233.90
Low
₹ 1,194.90
Mkt. cap
1.00ИН
Avg. vol.
1.67 сая
Volume
2.61 сая
Dividend
0.67%
Quarterly dividend
₹ 2.00
Ex-dividend date
2026 оны 7-р сарын 10
P/E ratio
31.08
52-wk high
₹ 1,414.90
52-wk low
₹ 1,101.00
EPS
₹ 38.67
Shares outstanding
166.06 сая
No. of employees
28 мян
Open
₹ 1,233.00
High
₹ 1,233.90
Low
₹ 1,194.90
Mkt. cap
1.00ИН
Avg. vol.
1.67 сая
Volume
2.61 сая
Dividend
0.67%
Quarterly dividend
₹ 2.00
Ex-dividend date
2026 оны 7-р сарын 10
P/E ratio
31.08
52-wk high
₹ 1,414.90
52-wk low
₹ 1,101.00
EPS
₹ 38.67
Shares outstanding
166.06 сая
No. of employees
28 мян
News stories
From web sources and news partners
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27.5 мян
Founded1984
HeadquartersХайдерабад, Андрапрадеш, Энэтхэг
SectorPharmaceutical industry
Last report
2026 оны 7-р сарын 22
Fiscal period
Q1 2027
EPS / Est. (INR)
₹ 5.33 / ₹ 9.13
-41.60%miss
Revenue / Est. (INR)
80.70 тэрбум / 81.12 тэрбум
-0.51%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
88.05 тэрбум
87.27 тэрбум
75.16 тэрбум
80.70 тэрбум
Cost of goods sold
39.91 тэрбум
40.46 тэрбум
41.47 тэрбум
43.16 тэрбум
Cost of revenue
39.91 тэрбум
40.46 тэрбум
41.47 тэрбум
43.16 тэрбум
Research and development expenses
6.20 тэрбум
6.15 тэрбум
5.46 тэрбум
5.77 тэрбум
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.44 тэрбум
26.92 тэрбум
27.76 тэрбум
28.82 тэрбум
Operating expense
31.90 тэрбум
32.48 тэрбум
32.53 тэрбум
34.11 тэрбум
Total operating expenses
71.81 тэрбум
72.94 тэрбум
74.00 тэрбум
77.27 тэрбум
Operating income
16.24 тэрбум
14.33 тэрбум
1.16 тэрбум
3.43 тэрбум
Other non operating income
1.28 тэрбум
570.00 сая
512.00 сая
-
EBT including unusual items
18.35 тэрбум
15.43 тэрбум
1.99 тэрбум
5.53 тэрбум
EBT excluding unusual items
17.81 тэрбум
15.52 тэрбум
1.82 тэрбум
4.09 тэрбум
Income tax expense
4.08 тэрбум
3.53 тэрбум
-214.00 сая
1.18 тэрбум
Effective tax rate
22.24%
22.90%
-10.75%
21.32%
Other operating expenses
-740.00 сая
-591.00 сая
-693.00 сая
-477.00 сая
Net income
14.37 тэрбум
12.10 тэрбум
2.20 тэрбум
4.44 тэрбум
Net profit margin
16.32%
13.86%
2.93%
5.50%
Earnings per share
17.87
14.77
5.74
5.33
Interest and investment income
912.00 сая
796.00 сая
890.00 сая
999.00 сая
Interest expense
-907.00 сая
-944.00 сая
-1.06 тэрбум
-1.26 тэрбум
Net interest expenses
5.00 сая
-148.00 сая
-167.00 сая
-256.00 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
21.29 тэрбум
19.54 тэрбум
5.03 тэрбум
8.80 тэрбум
Gain or loss from assets sale
-308.00 сая
-179.00 сая
-2.10 тэрбум
-368.00 сая
AI content may include mistakes. Learn more
Google аппс